RCS - BioMed X Institute - BioMed X Researches Drug Development with Sanofi

Sanofi SAAnnouncement

29/06/2023 13:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230629:nRSc0959Ea&default-theme=true

RNS Number : 0959E  BioMed X Institute  29 June 2023

BioMed X Institute Starts Its First Research Project With Sanofi on Artificial
Intelligence for Drug Development

Powered by Sanofi, a new BioMed X research team will develop a computational
platform designed to accelerate drug development.

HEIDELBERG, GERMANY / ACCESSWIRE / June 29, 2023 / BioMed X
(https://stats.newswire.com/x/html?final=aHR0cHM6Ly9iaW8ubXg&hit%2Csum=WyIzeTFkNXYiLCIzeTFkNXciLCIzeTFkNXgiXQ)
, a German independent research institute, announces the start of its first
research project in collaboration with Sanofi
(https://stats.newswire.com/x/html?final=aHR0cHM6Ly93d3cuc2Fub2ZpLmNvbS9lbg&hit%2Csum=WyIzeTFkNXkiLCIzeTFkNXoiLCIzeTFkNXgiXQ)
: "Next Generation Virtual Patient Engine for Clinical Translation of Drug
Candidates" (VPE). The end goal of this research project is to develop a
versatile computational platform that can predict the efficacy of first- or
best-in-class drug candidates in virtual patient populations at unprecedented
accuracy, thereby addressing one of the most critical bottlenecks of the
pharmaceutical industry today: a 90% failure rate of new drug candidates
during clinical development.

The new research team will be led by Dr. Douglas McCloskey, a scientist and
entrepreneur jointly selected by the Sanofi and BioMed X Institute management
for the group leader position. "Most drug candidates that fail during clinical
development do so due to a lack of efficacy compared to the standard of care.
Our mission is to develop a platform to test-drive drug development candidates
in virtual patients to gate the best ones into the clinic," explained the
newly-appointed group leader of team VPE. "To tackle this challenge, our team
at BioMed X will push the frontier of in silico drug discovery and development
using our AI expertise with coaching from our industry partners," added Dr.
McCloskey.

Christian Tidona, Founder and Managing Director of the BioMed X Institute:
"After two years of collaborating on AI-powered drug discovery and development
projects with our strategic partner in Israel, AION Labs, we are now ready to
start our first AI-based research team in Heidelberg, Germany, together with
our new pharma partner, Sanofi."

The "Next Generation Virtual Patient Engine for Clinical Translation of Drug
Candidates" (VPE) team joins eight other active research teams at the BioMed X
Institute in Germany, and it is one of four new projects launched by BioMed X
in 2023. To learn more about this new AI-based research group, visit the
BioMed X Institute website at www.bio.mx
(https://stats.newswire.com/x/html?final=aHR0cHM6Ly93d3cuYmlvLm14Lw&hit%2Csum=WyIzeTFkNjAiLCIzeTFkNjEiLCIzeTFkNXgiXQ)
.

About BioMed X

BioMed X is an independent research institute located on the campus of the
University of Heidelberg in Germany, with a worldwide network of partner
locations. Together with our partners, we identify big biomedical research
challenges and provide creative solutions by combining global crowdsourcing
with local incubation of the world's brightest early-career research talents.
Each of the highly diverse research teams at BioMed X has access to
state-of-the-art research infrastructure and is continuously guided by
experienced mentors from academia and industry. At BioMed X, we combine the
best of two worlds - academia and industry - and enable breakthrough
innovation by making biomedical research more efficient, more agile, and more
fun.

Contact Information

Flavia-Bianca Cristian

Recruiting & Communications Manager
fbc@bio.mx (mailto:fbc@bio.mx)

+49 6221 426 11 706

Related Image
(https://cdn.newswire.com/files/x/55/8a/b0081beb6904e79ee7c25e67bc0f.jpg)

SOURCE: BioMed X Institute

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABUGDLCGDDGXR